Heparin-modified chitosan/cellulose microsphere-based blood perfusion adsorbent as well as preparation method and application thereof

Abstract

The invention discloses a heparin-modified chitosan / cellulose microsphere-based blood perfusion adsorbent, belonging to the technical field of biological materials. The heparin-modified chitosan / cellulose microsphere-based blood perfusion adsorbent comprises cross-linked chitosan / cellulose microspheres, whreein a heparin coating is grafted outside the cross-linked chitosan / cellulose microspheres. The invention also discloses a preparation method and application of the heparin-modified chitosan / cellulose microsphere-based blood perfusion adsorbent. The adsorbent disclosed by the invention has relatively good mechanical strength and stability, so the requirement of blood perfusion on the mechanical strength of the blood perfusion adsorbent is better met; the adsorbent has rich positive charges due to rich amino groups in chitosan molecules, so endotoxin with negative charges can be efficiently removed; the heparin coating in the outer layer of the adsorbent can form a compound with histone, so the histone in the blood can be quickly removed; and he blood perfusion adsorbent disclosed by the invention can be used for removing various pathogenic factors in the blood of a sepsis patient through multiple adsorption targets, so the effect of blood purification treatment on the sepsis patient is enhanced.

Description

technical field [0001] The invention relates to the technical field of biological materials / blood contact materials, in particular to a hemoperfusion adsorbent based on heparin-modified chitosan / cellulose microspheres, a preparation method and application thereof. Background technique [0002] Sepsis is a series of clinical syndromes in which the body's immune system is dysregulated due to bacterial, viral or fungal infection, resulting in life-threatening organ dysfunction. Sepsis has a high incidence in critically ill patients and is the leading cause of death in critically ill patients. In my country, about 2.5 million people are diagnosed with sepsis every year, and about 700,000 people die of sepsis. At present, the treatment of sepsis mainly includes broad-spectrum antibiotic anti-infection therapy, fluid resuscitation, and vasopressor therapy when necessary; however, the therapeutic effect of these traditional treatments is poor, and the mortality rate of sepsis patie...

AI Technical Summary

Problems solved by technology

The applicant previously disclosed that a hemoperfusion adsorbent based on genipin cross-linked chitosan microspheres can effectively remove endotoxins and bacteria in the blood, but cannot yet adsorb histones (the hemoperfusion adsorbent based on chitosan and its application in the preparation of hemoperfusion for sepsis blood purification, patent number: ZL 2020 1 0095433.5)

[0010] Heparin is an anticoagulant substance extracted from the small intestinal mucosa of animals. It is a mucopolysaccharide sulfate composed of D-glucosamine, L-iduronic acid and D-glucuronic acid alternately. It has a high negative charge density. , can form complexes with histones through electrostatic interaction to neutralize the pathophysiological effects of histones and play an immunomodulatory role, but cannot directly remove histones from the plasma of patients with sepsis (Alhamdi Y, Abrams ST, Lane S, et al .Histone-associated thrombocytopenia in patients who are critically ill[J].JAMA,2016,315(8):817-819.)

Images